Table 2.
Multivariate Cox proportional hazards regression analysis for 1‐year progression‐free survival with inverse propensity score weighting (IPSW) adjustment
| Variable | Whole cohort | EGFR‐TKI responder | ||
|---|---|---|---|---|
| No adjustment | IPSW | No adjustment | IPSW | |
| Erlotinib | 1.17 (1.11–1.24) | 1.15 (1.09–1.21) | 1.11 (1.03–1.20) | 1.11 (1.03–1.17) |
| Male | 1.35 (1.27–1.42) | 1.38 (1.32–1.44) | 1.22 (1.14–1.32) | 1.26 (1.18–1.34) |
| Disease severity | ||||
| Operation | 0.73 (0.67–0.80) | 0.75 (0.69–0.80) | 0.71 (0.63–0.80) | 0.71 (0.64–0.78) |
| Cachexia | 1.20 (1.13–1.27) | 1.24 (1.19–1.30) | 1.15 (1.07–1.24) | 1.19 (1.12–1.27) |
| Duration of hospitalization (days) | 1.001 (1.000–1.001) | 1.001 (1.000–1.001) | 1.001 (1.000–1.001) | 1.001 (1.001–1.0014) |
| Packed red blood cell transfusion | 1.03 (1.02–1.04) | 1.04 (1.03–1.04) | 1.03 (1.14–1.32) | 1.03 (1.02–1.04) |
Multivariate Cox regression adjusted for gender, age, disease severity (operation, cachexia, increased intracranial pressure, duration of hospitalization [days], and transfusion), comorbidities (chronic obstructive pulmonary disease, diabetic mellitus, chronic kidney disease, tuberculosis, liver cirrhosis, autoimmune disease, transplantation, acquired immunodeficiency syndrome, and other malignancies), and low income.
Data were hazards ratio and 95% confidence interval.
EGFR‐TKI, epidermal growth factor receptor‐tyrosine kinase inhibitors.